Anaveon To Take A Different Clinical Path With Novel IL-2 Therapy

Interleukin-2 Agonist Being Assessed In Solid tumors

 
• By Sten Stovall
Cancer cells on scientific background.3d illustration
Anaveon CEO Tells Scrip Compound Can Improve On Limitations Posed By Interleukin-2 • Source: Shutterstock

More from Clinical Trials

More from R&D